: Drug Design & Medicinal Chemistry

Drug Design & Medicinal Chemistry

26 - 27 October 2021 | London, UK
+ Digital Day: 28 October 2021 | Online
9th Annual
Drug Design & Medicinal Chemistry Congress
26 - 27 October 2021 | London, UK
+ Digital Day: 28 October 2021 | Online

Bringing you the latest in enabling technologies, computational-based drug design and discovery chemistry. Key focus areas include: DNA-encoded libraries, protein-to-protein interactions, AI/ML in drug design, and medicinal chemistry for oncology

Drug Design and Medicinal Chemistry Congress includes...​

Join over 400 leaders, experts and scientists at this event, helping to shape the future of discovery chemistry and computational drug design:

Learn about key focus areas include DNA encoded libraries, protein-protein interactions, AI/ML in drug design and new modalities such as Protein Degradation and Covalent Inhibitors.

Gain successful strategies in compound library development, DNA/RNA encoded libraries, protein to protein interaction, fragment and structured based drug design

Focusing on cutting edge tools, including: AI in ADME, big data management, model management, artificial intelligence, machine learning in drug design and AI in chemical synthesis, AI-enabled target ID capabilities, lead identification/optimisation

Engage in interactive discussions on the Integration Of DEL, Covalent Inhibitors and Protein Degradation Technologies In The Optimization Of HITs.

Supported digitally on our fully featured online event platform, with selected presentations available to watch on-demand and extensive networking features.

Agenda at a Glance

Day One

Morning Sessions:

Stream 4: Computational Drug Design: AI Focus

Afternoon Interactive Roundtable Sessions:

Roundtable Discussions:

  • Addressing Difficult Targets with New Novel Approaches in Drug Design
  • AI in Drug Design – Where Are We?
  • Digitising Drug Discovery Labs
  • AI & Data Analysis


Workshop: 
Deploying 3D Modelling To Chemists

Day Two

Stream 3: Integration Of Technologies In The Optimization Of HITs – DEL, Covalent Inhibitors and Protein Degradation

Stream 4: Molecular Drug Design and Medicinal Chemistry

Interactive Roundtable Discussions:

  • New Chemical Modalities and Challenging Targets: (Small and Large Molecules) and Choice of Modalities
  • Covalent Inhibitors Design and Discovery – Overcoming Challenges

Key Speakers

The 2021 event again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data and industry outlook.

Ian Storer

Ian Storer

Vice President of Chemistry and Hit Discovery
AstraZeneca
Malcolm Weir

Malcolm Weir

Chief Executive Officer
Sosei Heptares
Thorsten Thormann

Thorsten Thormann

Vice President, Research
Leo Pharma
Janet Brownlees

Janet Brownlees

Director, Neuroscience Biology, Discovery Research MRL UK
MSD
Sarah Stuart

Sarah Stuart

HTC Team Leader, Biopharm Discovery
GSK
Bryn Williams-Jones

Bryn Williams-Jones

Vice President Drug Discovery
BenevolentAI
Victor Neduva

Victor Neduva

Director of Computational Biology, Discovery Research
MSD
Jake Bush

Jake Bush

Director Chemical Biology
GSK
Eric Martin

Eric Martin

Director, Computational Chemistry
Novartis
Phil Cox

Phil Cox

Research Fellow, Head of Augmented Molecular Design, Drug Discovery Science and Technology
AbbVie

Copyright Oxford Global Marketing Limited. All rights reserved.

Live Webinar

Application of In-Vitro and In-Vivo ADME/PK/Expl Tox assays to Support Lead and Candidate Selections

Wednesday, 18th November, 2020
10:00am GMT (UTC+0)

hosted by Lilly Xu, Ph.D. Senior Vice President, DMPK & Exploratory Toxicology Dept, ChemPartner